ProstaLund

Mindre end 1K følgere

Oversigt

Investorkonsensus

Alle

Selskabsmeddelelser

Eksterne analyser

ViserAlle indholdstyper

Selskabsmeddelelse24.10.2025, 05.30

PROSTALUND AB (publ) - Interim report January-September 2025

Pressemeddelelse12.9.2025, 06.00

ProstaLund enters collaboration agreement with the XEN Group for the market in the United Arab Emirates and Oman

Pressemeddelelse10.9.2025, 06.00

ProstaLund enters collaboration agreement with Mayumana Healthcare for the Benelux market

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto

Følgere og notifikationer om fulgte virksomheder

Analytikerkommentarer og anbefalinger

Værktøj til at sammenligne aktier og andre populære værktøjer

Selskabsmeddelelse21.8.2025, 05.30

ProstaLund AB - Interim Report January-June 2025

Pressemeddelelse26.6.2025, 14.45

First CoreTherm® Eagle treatments performed in Denmark

Pressemeddelelse17.6.2025, 08.00

Second clinic in Sweden starts treatment with CoreTherm® Eagle

Selskabsmeddelelse30.5.2025, 05.30

ProstaLund AB - Interim report January-March 2025

Pressemeddelelse20.5.2025, 13.50

First patients treated with CoreTherm® Eagle

Pressemeddelelse14.5.2025, 08.45

First treatments with CoreTherm® Eagle to be performed next week – Key milestone for ProstaLund

Pressemeddelelse24.2.2025, 14.00

Correction: Use of the Schelin Catheter® prior to water vapor thermal therapy shown to be cost-effective

Pressemeddelelse24.2.2025, 08.05

Use of the Schelin Catheter® prior to water vapor thermal therapy shown to be cost-effective

Selskabsmeddelelse20.2.2025, 06.30

ProstaLund AB - Year-end report 2024

Pressemeddelelse14.2.2025, 14.45

New study confirms the strong efficacy of CoreTherm® in patients with large prostates

Pressemeddelelse27.1.2025, 09.00

Elderly men treated with CoreTherm® for benign prostatic hyperplasia have lower risk for a prostate cancer diagnosis later in life compared to men treated with TURP, according to a new Swedish register study

Pressemeddelelse10.12.2024, 08.00

Additional study published confirming effectiveness of transurethral intraprostatic anaesthesia (TUIA) using our Schelin Catheter® during benign prostatic enlargement treatments

Eksterne analyser11.11.2024, 12.11

ProstaLund: CoreTherm Eagle flygfärdig - VH Corp

* Tio CoreTherm Eagle-maskiner är tillverkade * Förbättrat patientflöde jämfört med första halvåret * Vi behåller vårt motiverade värde om 0,81 SEK per aktie ProstaLunds nettoomsättning i Q3 om 3,5 MSEK var klart lägre jämfört med samma period 2023. ...

Pressemeddelelse7.11.2024, 11.00

The first ten CoreTherm® Eagle machines are manufactured

Selskabsmeddelelse7.11.2024, 06.30

Interim report January-September 2024

Pressemeddelelse11.10.2024, 08.00

Short-term results and long-term durability after CoreTherm® treatments presented at the Emirates International Urological Conference in Dubai, UAE

Pressemeddelelse4.10.2024, 11.00

First published report of transurethral intraprostatic anaesthesia (TUIA) using the Schelin Catheter® in patients undergoing holmium laser enucleation of the prostate

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.